706 results about "Ascites" patented technology

A transvesicular drainage device, designed to drain excess fluid from a variety of locations in the human body into the bladder. The device may be used to treat ascites or any fluid collection within the body of a human, or a non human mammal.

A single, integrated device in which a body fluid (e.g., blood) of a human or animal can be both collected and analyzed easily and without risk of contamination is disclosed. The collection portion and analysis portion of the device are permanently joined to permit movement of small quantities of body fluid under controlled conditions, to minimize any waste of the body fluid, to ensure that no contamination reaches the main body fluid volume, and to create a permanent physical record of the results of the analysis in association with the fluid sample itself: A wide variety of different body fluid components which may be indicative of various diseases, dysfunctions and abnormalities of the human or animal or the body fluid itself can be tested for. The device includes a container for collecting human or animal body fluid, one or more testing chambers containing one or more analysis units activated by body fluid; a transfer pump or vacuum assembly to transfer one or more samples into the analysis units; and one-way valves or the equivalent to prevent any portion of the withdrawn sample from being returned to the collection container. The body fluid acted upon may be blood, blood plasma, urine, bile, pleural fluid, ascites fluid, stomach or intestine fluid, colostrom, milk or lymph.

The presence of tumor nodules in organs often results in serious clinical manifestations and the permeation by cancer cells of sheaths surrounding organs often produces clinical manifestations of pleural effusion, ascites or cerebral edema. The present invention addresses this problem by providing a method for treating tumors comprising (a) intratumoral administration of a superantigen and/or (b) intrathecal or intracavitary administration of a superantigen directly into the sheath. Intratumoral superantigen results in significant and sustained reduction of the tumor size. Intrathecal administration produces significant sustained reduction of the fluid accumulation associated with clinical improvement and prolonged survival. Useful superantigen compositions for intrathecal and intratumoral injection include tumoricidally effective homologues, fragments and fusion proteins of native superantigens. Also disclosed is combined therapy that includes intratumoral or intrathecal superantigen compositions in combination with (i) intratumoral low, non-toxic doses of one or more chemotherapeutic drugs or (ii) systemic chemotherapy at reduced and non-toxic doses of chemotherapeutic drugs.

A fluid management system for the treatment of ascites, pleural effusion or pericardial effusion is provided including an implantable device including a pump, control circuitry, battery and transceiver; a charging and communication system configured to periodically charge the battery and communicate with the implantable device to retrieve performance data; and monitoring and control software, suitable for use with conventional personal computers, for configuring and controlling operation of the implantable device and charging and communication system. The implantable device includes a number of features that provide automated movement of fluid to the bladder with reduced risk of clogging, with no patient involvement other than occasional recharging of the battery of the implantable device. The monitoring and control software is available only to the treating physician, such that the physician interacts with the implantable device via the charging and communication system.

The invention discloses a new traditional Chinese medicine composition for treating advanced malignant liver tumor symptoms and a preparation method thereof. The traditional Chinese medicine composition is mainly prepared from the following medicine components: angelica, tuckahoe, hemlock parsley, cassia twig, dried ginger, Bupleurum, kudzu root, Baikal skullcap root, coptis, flavescent sophora root, honeysuckle, Taraxacum, pangolin, leech, natural indigo, subprostrate sophora, moutan bark, red-rooted salvia root, red paeonia, white peony root, white atractylodes rhizome, gromwell, cornu antelopis powder, rhubarb, magnolia bark, three-nerved spicebush root, notoginseng, madder, draconis sanguis, rhizoma corydalis, raw Astragalus root, codonopsis pilosula, peach seed, safflower, turmeric, Endothelium Corneum Gigeriae Galli, Fructus Aurantii Immaturus, Polyporus umbellatus, rhizoma alismatis, Plantain seed, climbing fern spore, giant knotweed, Evodia rutaecarpa, nut grass, galangal and allium macrostemon. The traditional Chinese medicine composition can be prepared into any commonly-used oral preparation by using the conventional traditional Chinese medicine preparation method. The traditional Chinese medicine composition can be prepared into any commonly-used oral preparation by using the conventional traditional Chinese medicine preparation method. The invention can obviously improve the intense pain, obstructs the canceration of liver tumor cells, interdicts the reproduction of tumor cells, recovers the activity of liver cells, enhances the self-repairing function of the liver, resists the diffusion and prevent the metastasis, obviously shrinks the liver tumors, relieves and eliminates the ascites, improves the life quality, prolongs the life, relieves patient's pain and increases the appetite. The traditional Chinese medicine composition has exact and obvious clinical curative effect of improving the overall disease resistance.

The invention describes the use of a pharmaceutical preparation containing a trifunctional bispecific and/or trispecific having the following properties:

• a) binding to a T cell;
• b) binding to at least an antigen on a tumor cell associated with malignant ascites and/or pleural effusion;
• c) binding, by its Fc portion (in the case of bispecific antibodies) or by a third specificity (in the case of trispecific antibodies), to Fc receptor-positive cells for the destruction of the tumor cells in the treatment of malignant ascites and/or pleural effusion.

An anticancer high-molecular precursor medicine C-Spacer-P, where P is high- molecular pectin, C is an anticancer medicine containing amino radical or hydroxy radical, and Spacer is the spacing radical, is prepared by bonding the amino or hydroxy of an anticancer medicine with the hydroxy, carboxy, or hydroxymethyl of high- molecular pectin via spacing radical. It is an injection suitable for the solid cancer, and cancerous ascites or hydrothorax.

The invention discloses a microcystlin monoclonal antibody and the preparation method and the application thereof. The microcystlin monoclonal antibody is a microcystlin-LR monoclonal antibody, and the preparation method thereof is that: 1) an amino group is introduced to a seventh amino acid residue N-methyl dehydroalanine on microcystlin-LR, thus obtaining amino modified microcystlin-LR polypeptide; the amino modified microcystlin-LR polypeptide is coupled with carrier protein to obtain complete A antigen; 2) the immunity mouse of complete A antigen obtained in step 1) to get spleen cell of immunity mouse, which then is fused with myeloma cell of mouse to screen out positive hybrid cancer cell strain; the positive hybrid cancer cell strain is cultured or is injected in sygeneous mouse abdominal cavity to induce ascites to get the microcystlin-LR monoclonal antibody. The monoclonal antibody can be used for examining microcystlin-LR and immunity affinity purification thereof.

The present invention provides methods for selecting a suitable anticancer therapy and for identifying and predicting response for the treatment of a gastric cancer by determining the expression level and/or activation level of one or more analytes in a cell such as a cancer cell from an ascites sample. The present invention also provides methods for selecting a suitable anticancer therapy and for identifying and predicting response for the treatment of a lung cancer such as a non-small cell lung cancer by determining the expression level and/or activation level of one or more analytes in a cell such as a cancer cell from a pleural efflux sample.

The present invention relates to a method for reducing infarction comprising administering to a patient ion need thereof a therapeutically effective amount of a composition comprising as an active ingredient a vasopressin antagonist compound and to a composition useful therefor. The present invention also relates to a method for reducing infarction comprising administering to a patient in need thereof a therapeutically effective amount of a combination of a vasopressin antagonist compound and a beta-blocker and to combinations useful therefor. The methods, compositions and combinations of the present invention can be used for reducing infarction in the heart (myocardial infarction) and the brain (stroke). The methods, compositions and combinations of the present invention can also be used for the treatment and/or prevention of hypertension, edema, ascites, heart failure, renal function disorder, vasopressin inappropriate secretion syndrome (SIADH), hepatocirrhosis, hyponatremia, hypokalemia, polycystic kidney disease, diabetes, or circulation disorder.

The invention relates to a feed additive, in particular to the feed additive of the traditional Chinese medicine for curing broiler ascites and a preparation method thereof. The invention solves the problem that amounts of chicken are dead due to the broiler ascites in the course of dorking feeding. The feeding additive comprises the following components by weight proportion: 4-6% of prepared aconite, 4-6% of rhizoma zingiberis, 2-3% of liquorice, 9-11% of radix astragali, 7-8% of the rhizome of large-headed atractylodes, 7-8% of dried orange peel, 9-10% of tuckahoe, 7-8% of agaric, 9-11% of alisma orientale, 7-8% of shell of areca nut, 9-11% of rhizoma imperatae, 7-8% of semen plantaginis, and 9-11% of the seed of Job's tears. The preparation method is as follows: all Chinese medicine herbs are respectively put into a muller for crashing, put into a blender for fully stirring and well bended, and then are crashed, sieved with 80 meshes, and then are packed; the finished goods are obtained. The feed additive has reasonable formulation, easy implementation and is a non-polluted feeder additive with high quality.

The present invention is directed to imidazolyl derivatives of the formula:

where the substituents are defined in the specification, or a pharmaceutically acceptable salt thereof. The derivatives bind selectively to the somatostatin subtype receptors and elicit either an agonist or antagonist effect from the somatostatin subtype receptors. The derivatives are useful for treating a variety of diseases including acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, hypotension, postprandial hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas.

The invention discloses a method for effectively culturing tumor infiltrating lymphocytes (TILs). The method comprises the following steps: extracting mononuclear cells from the pectoral ascite or tumor tissue of a patient, washing, inoculating into a culture bottle coated with recombinant human fibrin and cluster-of-differentiation-3 antibody, culturing for 24 hours, adding interleukin II, then using a serum-free culture medium containing the interleukin II and the supernatant pectoral ascite to enlarge and subculture every two or three days, and adding apoptosis-regulated protein survivin and mucoprotein-1 on the twelveth or thirteenth day to activate the killing activity; and harvesting cells on the fourteenth day. By adopting the method, the culture time, which is only 14 days, is greatly shortened, so that the hospital stays of the patient can be greatly shortened and the hospital burden of the patient can be reduced. Meanwhile, the problems that the cell proliferation speed is low and the proliferation ratio is low can be solved, thus the number of the cultured cells can meet the clinical requirement. The cultured TILs has strong cell specificity so as to enhance the clinical curative effect.

A method for determining whether a patient has a particular type of cancer which comprises: a. obtaining an ascites, abnormal cell cellular fluid or serum sample from the patient;

• • b. diluting the sample with D₂O;
  • c. subjecting the sample to ¹HNMR to obtain a series of free induction decay outputs (FID's);
  • d. mathematically modifying the data to obtain ¹HNMR spectra;
  • e. correcting the ¹HNMR spectra for phase and baseline distortions;
  • f. data reducing the corrected ¹HNMR spectra to obtain a plurality of integral spectral segments; g. compensating for effects of variation in suppression of water resonance;
  • h. normalizing the resulting data to total spectral area to obtain normalized ¹HNMR spectra;
  • i. subjecting the normalized ¹HNMR spectra to principal component analysis to obtain normalized data; and j. plotting and comparing the normalized data with corresponding control data indicating the presence of the particular type of cancer to determine whether the sample indicates that the patient has the particular type of cancer.

A hybridoma producing a monoclonal antibody recognizing the C-terminus of human brain natriuretic peptide (hBNP) was cultivated in a medium or the abdominal cavity of a mouse to recover the monoclonal antibody from the medium or ascites accumulated in the abdominal cavity. An immunoassay for hBNP was established using the monoclonal antibody. The immunoassay for hBNP of the invention is so sensitive that the minimum detection limit is 1 pg/ml and can therefore determine the hBNP level in blood plasma directly, without the extraction of hBNP from blood plasma. It is useful for diagnosing diseases such as hypertension and the like, and states of the heart, kidney, and the like by using the increase/decrease of the hBNP level as an index.

The invention discloses a new traditional Chinese medicine composition for treating min-term malignant liver tumor symptoms and a preparation method thereof. The traditional Chinese medicine composition is mainly prepared from the following medicine components: pangolin, red-rooted salvia root, tuckahoe, angelica, white peony root, red-rooted salvia root, peach seed, safflower, rhizoma sparganii, Rhizoma Zedoariae, giant knotweed, Chinese rrichosanthes root, coptis, flavescent sophora root, red paeonia, gromwell, orientvine, magnolia bark, Evodia rutaecarpa, Fructus Aurantii Immaturus, costus root, rhizoma cyperi, notoginseng, mastic, myrrh, draconis sanguis, Bupleurum, kudzu root, dandelion, madder, hyacinth bletilla, sanguisorba, ganoderma lucidum, ground beetle, agilawood, leech, vallicepobufagin, raw Astragalus root, ginseng and white atractylodes rhizome. The traditional Chinese medicine composition can be prepared into any commonly-used oral preparation by using the conventional traditional Chinese medicine preparation method. The invention can obviously improve the liver tumors and the symptoms of the abnormity of the liver function, the liver cell trauma, the hepatalgia, the hepatocirrhosis, the liver ascites and the like, obviously shrink the liver tumours, recover the liver function, activate the activity of the stem cells, regulate qi, remove the stasis, decrease the swelling, relieve the pain, enhance the body resistance to diseases, and obviously improve the life quality. The traditional Chinese medicine composition has exact and obvious clinical curative effect, high efficiency and quick action. By basically combining edible and pharmaceutical products specified in the national pharmacopoeia, the traditional Chinese medicine composition has the advantages of low cost, no toxic or side effects and the like.

The invention discloses a novel Chinese medicinal composition for treating edema and a preparation method thereof. The Chinese medicinal composition mainly comprises the following raw material medicaments: Indian buead, largehead atractylodes rhizome, common yam rhizome, pyrrosia leaf, ricepaperplant pith, Mongolian snakegourd root, immature bitter orange, Szechwan chinaberry fruit, Chinese eaglewood, green tangerine peel, Chicken's gizzard-membrane, mix-fried pangolin scales, rhubarb, atraotydin, officinal magnolia bark, coix seed, oriental waterplantain rhizome, plantain seed, Japanese climbing fern spore, cassia twig, ash bark, lightyellow sophora root, densefruit pittany root-bark, gentian, glossy privet fruit, turtle shell, tortoise plastron, Chinese leek seed and the like. The Chinese medicinal composition can be prepared into any common oral preparation by the conventional Chinese medicinal preparation method. The Chinese medicinal composition can obviously improve symptoms such as edema, dropsy of limbs and faces, ascites, pleural effusion, seroperitoneum, hydrophobia and the like. The Chinese medicinal composition has the advantages of exact clinical effects, obvious curative effect, quick response, low cost, basically no toxic or side effects and the like.

We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an XL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.

A system for noninvasively monitoring cancerous cells within bodily fluid accumulated due to ascites, pleural effusion or pericardial effusion is provided including an implantable pump having control circuitry; a charging and communication system configured to periodically charge and communicate with the implantable pump to retrieve performance data; and monitoring and control software, suitable for use with conventional personal computers, for configuring and controlling operation of the implantable pump and charging and communication system. The implantable pump is configured to move fluid containing cancerous cells from a body cavity to the bladder such that the fluid may be excreted during urination, collected and analyzed with an analysis station to assess progress of the cancer or efficacy of a cancer treatment program.

The present invention provides agents for alleviating symptoms resulting from inflammation, which have an activity to alleviate inflammatory symptoms caused by bacterial infection, particularly accumulation of body fluid such as bronchocavernous plasma exudation, ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils; symptoms resulting from inflammation caused by bacterial infection, particularly accumulation of body fluid such as bronchocavernous plasma exudation ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils, can be alleviated effectively by ingesting or administering orally or parenterally a composition containing human-type lactoferrin as an effective component.

A fluid management system for moving bodily fluid accumulated due to ascites, pleural effusion or pericardial effusion is provided including an implantable pump coupled to an inflow catheter, an outflow catheter, and optionally an anti-clog catheter. The fluid management system facilitates removal of fluid from a body region, such as the peritoneum, pleural cavity or pericardial sac, where drainage is desired to another body region, such as the urinary bladder or the peritoneal cavity. The system includes clog resistant mechanisms such as clog resistant catheters and/or programmed routines for cycling fluid through inlet catheters in predetermined time intervals and/or responsive to sensed conditions to minimize the risk that inlet catheters become clogged due to, for example, tissue ingrowth and/or solid objects within accumulated fluid.